Comparative Pharmacology
Head-to-head clinical analysis: BUMEX versus ETHACRYNATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMEX versus ETHACRYNATE SODIUM.
BUMEX vs ETHACRYNATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Category C
Category C
Loop Diuretic
Loop Diuretic